Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
132 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015', provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 10 Therapeutics Development 11 Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 11 Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis 12 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies 13 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes 16 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies 21 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes 24 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 25 Aeolus Pharmaceuticals, Inc. 25 Bolder Biotechnology, Inc. 26 Cantex Pharmaceuticals, Inc. 27 Cellerant Therapeutics, Inc. 28 Cleveland BioLabs, Inc. 29 Gamida Cell Ltd. 30 Humanetics Corporation 31 Meabco A/S 32 NeoStem, Inc. 33 Neumedicines Inc. 34 Onconova Therapeutics, Inc. 35 Piramal Enterprises Limited 36 Pluristem Therapeutics Inc. 37 Priaxon AG 38 ProCertus BioPharm Inc. 39 RDD Pharma Ltd. 40 RxBio, Inc. 41 Soligenix, Inc. 42 Terapio Corporation 43 Tonix Pharmaceuticals Holding Corp. 44 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Target 46 Assessment by Mechanism of Action 48 Assessment by Route of Administration 50 Assessment by Molecule Type 52 Drug Profiles 54 517-PXN - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 AEOL-10171 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 BBT-007 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 BBT-015 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 BBT-018 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 BBT-045 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 BCN-057 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 BIO-300 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 BP-C2 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 CLT-009 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 EDL-2000 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 entolimod - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 EWA-001 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 GC-003 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 GC-4403 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 GC-4419 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 JP4-039 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 NMIL-121 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 P-276 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 PGX-100 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 PLX-RAD - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 PrC-210 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 recilisib sodium - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute radiation syndrome and Ischemic organ injury - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 romyelocel-L - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 RP-239X - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 rusalatide acetate - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Rx-100 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 RX-101 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 SGX-201 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Small Molecule for Radiation Proctitis - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Small Molecules for Radiation and Chemical Toxicity - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Small Molecules for Radiation Toxicity - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 ST-7 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 Stem Cell Therapy for Radiation Exposure - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 SY-303A - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 SY-513 - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 TPO-7630 - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Recent Pipeline Updates 108 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 120 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 123 Featured News & Press Releases 123 Jan 12, 2015: Cleveland BioLabs Receives Department of Defense Support to Further Development of Entolimod as a Medical Radiation Countermeasure 123 Sep 11, 2014: Cellerant Awarded $47.5 Million Under Existing U.S. Government Contract to Support Development of CLT-008 123 Sep 03, 2014: Cleveland BioLabs Announces Green Light to Submit Pre-Emergency Use Authorization Application for Entolimod 124 Apr 18, 2014: Neumedicines Publishes Clinical Data Demonstrating Safety and Hematopoietic and Immune Effects of HemaMax (rHuIL-12), a Radiation Medical Countermeasure 125 Apr 15, 2014: Neumedicines Announces Publication of Phase II-Equivalent Data Demonstrating the Survival Effect of HemaMax (rHuIL-12), a Radiation Medical Countermeasure 126 Feb 25, 2014: Humanetics Enters Into Cooperative Research and Development Agreement With the U.S. Army Medical Research Institute of Chemical Defense 127 Feb 03, 2014: U.S. National Institutes of Health to Commence New Study of Pluristem's PLX Cells for Acute Radiation Syndrome Treatment 127 Jan 23, 2014: Cleveland BioLabs Provides Update on Barda Development Proposal 128 Jan 09, 2014: Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference 128 Dec 13, 2013: Neumedicines Presents HemaMax Clinical Data at the ASH Conference 129 Appendix 131 Methodology 131 Coverage 131 Secondary Research 131 Primary Research 131 Expert Panel Validation 131 Contact Us 131 Disclaimer 132
List of Tables Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2015 11 Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H1 2015 12 Number of Products under Development by Companies, H1 2015 14 Number of Products under Development by Companies, H1 2015 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2015 16 Comparative Analysis by Late Stage Development, H1 2015 17 Comparative Analysis by Clinical Stage Development, H1 2015 18 Comparative Analysis by Early Stage Development, H1 2015 19 Comparative Analysis by Unknown Stage Development, H1 2015 20 Products under Development by Companies, H1 2015 21 Products under Development by Companies, H1 2015 (Contd..1) 22 Products under Development by Companies, H1 2015 (Contd..2) 23 Products under Investigation by Universities/Institutes, H1 2015 24 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 25 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H1 2015 26 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 27 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H1 2015 28 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H1 2015 29 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Gamida Cell Ltd., H1 2015 30 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H1 2015 31 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H1 2015 32 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by NeoStem, Inc., H1 2015 33 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H1 2015 34 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H1 2015 35 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Piramal Enterprises Limited, H1 2015 36 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H1 2015 37 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Priaxon AG, H1 2015 38 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ProCertus BioPharm Inc., H1 2015 39 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd., H1 2015 40 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H1 2015 41 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H1 2015 42 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H1 2015 43 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 44 Assessment by Monotherapy Products, H1 2015 45 Number of Products by Stage and Target, H1 2015 47 Number of Products by Stage and Mechanism of Action, H1 2015 49 Number of Products by Stage and Route of Administration, H1 2015 51 Number of Products by Stage and Molecule Type, H1 2015 53 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics - Recent Pipeline Updates, H1 2015 108 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2015 120 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..1), H1 2015 121 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..2), H1 2015 122
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.